Researchers in the United Kingdom have completed initial clinical trials of a vaccine technology that eliminates the need for refrigeration, addressing a significant global health challenge. The trial involved 60 volunteers who received a modified version of a tetanus-diphtheria vaccine that had been converted into a dry powder and stored at room temperature for a year before being reconstituted with water for injection.
Currently, the majority of vaccines require strict temperature control throughout manufacturing, storage, and transportation—a requirement known as the “cold chain.” This dependency creates substantial challenges, particularly in developing regions and conflict areas where reliable electricity and refrigeration infrastructure are limited. The World Health Organization estimates that approximately half of all vaccines manufactured globally are wasted annually, with cold chain failures representing a major contributing factor alongside transportation damage and expiration.
The breakthrough technology uses trehalose, a sugar found in resurrection plants that naturally survive extreme droughts by drying out completely. Researchers applied this biological principle to stabilize vaccine components, allowing them to remain viable without refrigeration. According to Prof Saul Faust, director of the NIHR Clinical Research Facility in Southampton, the stabilized vaccine produced immune responses equivalent to conventional vaccines while demonstrating safety and tolerability in early-stage studies.
The research meets World Health Organization targets for vaccines stable at 30 degrees Celsius with 75 percent relative humidity. Additional data indicates the vaccine components survive temperature cycling between minus 20 degrees Celsius and plus 40 degrees Celsius, suggesting viability through realistic transportation scenarios involving aircraft cargo holds and heated vehicles. A larger trial involving 160 participants is scheduled to begin in the coming months, representing the final research phase since the original vaccine formulation is already approved and licensed.
While the technology cannot be adapted for newer mRNA vaccines, researchers indicate many existing vaccines and certain refrigerated medicines could potentially be stabilized using this approach. Larger studies in ethnically diverse populations and further investigation of temperature stability under fluctuating conditions remain areas for additional research before widespread implementation.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI